Merck KGaA removed several clinical‑stage oncology assets acquired via its SpringWorks purchase, including a Hippo pathway inhibitor (SW‑682) and a PARP1 inhibitor (M9466), after a strategic portfolio review. The company confirmed it will not pursue certain prior indications and said investigator‑led research may continue. The cuts reflect Merck KGaA’s post‑acquisition reprioritization and signal tighter internal prioritization across oncology R&D amid pressures from generics and shifting corporate strategy.